When immune cells turn bad—tumor-associated microglia/macrophages in glioma

International Journal of Molecular Sciences

Volumn 19, Issue 2, 2018, Pages

  Roesch, Saskia ^a   Rapp, Carmen ^a   Dettling, Steffen ^a   Herold Mende, Christel ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

GAMs; GBM; Glioblastoma; Glioma; Glioma associated microglia macrophages; Microglia; TME; Tumor microenvironment

Indexed keywords

3 (6 BROMO 2 PYRIDINYL) 2 CYANO N (1 PHENYLETHYL)ACRYLAMIDE; ATEZOLIZUMAB; CD68 ANTIGEN; EMACTUZUMAB; PEXIDARTINIB; PLERIXAFOR; CYTOKINE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CELL ACTIVATION; CELL INVASION; CENTRAL NERVOUS SYSTEM; EXTRACELLULAR MATRIX; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOBIOLOGY; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MICROGLIA; MOLECULAR INTERACTION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POLARIZATION; REVIEW; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; BIOLOGICAL MODEL; BRAIN; BRAIN TUMOR; IMMUNOLOGY; MACROPHAGE; METABOLISM; PATHOLOGY;

ANIMALS; BRAIN; BRAIN NEOPLASMS; CYTOKINES; GLIOMA; HUMANS; MACROPHAGES; MICROGLIA; MODELS, IMMUNOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 85041719762     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms19020436     Document Type: Review

References (166)

1. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.B.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987–996. [CrossRef] [PubMed]
2. DeWitt, J.C.; Mock, A.; Louis, D.N. The 2016 WHO classification of central nervous system tumors: What neurologists need to know. Curr. Opin. Neurol. 2017, 30, 643–649. [CrossRef] [PubMed]
3. Quail, D.F.; Joyce, J.A. The Microenvironmental Landscape of Brain Tumors. Cancer Cell 2017, 31, 326–341. [CrossRef] [PubMed]
4. Haddad-Tóvolli, R.; Dragano, N.R.V.; Ramalho, A.F.S.; Velloso, L.A. Development and Function of the Blood-Brain Barrier in the Context of Metabolic Control. Front. Neurosci. 2017, 11, 224. [CrossRef] [PubMed]
5. Prinz, M.; Priller, J. The role of peripheral immune cells in the CNS in steady state and disease. Nat. Neurosci. 2017, 20, 136–144. [CrossRef] [PubMed]
6. Raes, G.; Van den Bergh, R.; De Baetselier, P.; Ghassabeh, G.H.; Scotton, C.; Locati, M.; Mantovani, A.; Sozzani, S. Arginase-1 and Ym1 Are Markers for Murine, but Not Human, Alternatively Activated Myeloid Cells. J. Immunol. 2005, 174, 6561–6562. [CrossRef] [PubMed]
7. Hambardzumyan, D.; Gutmann, D.H.; Kettenmann, H. The role of microglia and macrophages in glioma maintenance and progression. Nat. Neurosci. 2016, 19, 20–27. [CrossRef] [PubMed]
8. Graeber, M.B.; Scheithauer, B.W.; Kreutzberg, G.W. Microglia in brain tumors. Glia 2002, 40, 252–259. [CrossRef] [PubMed]
9. Poon, C.C.; Sarkar, S.; Yong, V.W.; Kelly, J.J.P. Glioblastoma-associated microglia and macrophages: Targets for therapies to improve prognosis. Brain J. Neurol. 2017, 140, 1548–1560. [CrossRef] [PubMed]
10. Davies, L.C.; Jenkins, S.J.; Allen, J.E.; Taylor, P.R. Tissue-resident macrophages. Nat. Immunol. 2013, 14, 986–995. [CrossRef] [PubMed]
11. Ginhoux, F.; Greter, M.; Leboeuf, M.; Nandi, S.; See, P.; Gokhan, S.; Mehler, M.F.; Conway, S.J.; Ng, L.G.; Stanley, E.R.; et al. Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages. Science 2010, 330, 841–845. [CrossRef] [PubMed]
12. Kierdorf, K.; Erny, D.; Goldmann, T.; Sander, V.; Schulz, C.; Perdiguero, E.G.; Wieghofer, P.; Heinrich, A.; Riemke, P.; Hölscher, C.; et al. Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat. Neurosci. 2013, 16, 273–280. [CrossRef] [PubMed]
13. Casano, A.M.; Peri, F. Microglia: Multitasking specialists of the brain. Dev. Cell 2015, 32, 469–477. [CrossRef] [PubMed]
14. Fu, R.; Shen, Q.; Xu, P.; Luo, J.J.; Tang, Y. Phagocytosis of microglia in the central nervous system diseases. Mol. Neurobiol. 2014, 49, 1422–1434. [CrossRef] [PubMed]
15. Gomez Perdiguero, E.; Klapproth, K.; Schulz, C.; Busch, K.; Azzoni, E.; Crozet, L.; Garner, H.; Trouillet, C.; de Bruijn, M.F.; Geissmann, F.; et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature 2015, 518, 547–551. [CrossRef] [PubMed]
16. Hickey, W.; Kimura, H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 1988, 239, 290–292. [CrossRef] [PubMed]
17. Epelman, S.; Lavine, K.J.; Randolph, G.J. Origin and functions of tissue macrophages. Immunity 2014, 41, 21–35. [CrossRef] [PubMed]
18. Hutchins, K.D.; Dickson, D.W.; Rashbaum, W.K.; Lyman, W.D. Localization of morphologically distinct microglial populations in the developing human fetal brain: Implications for ontogeny. Brain Res. Dev. Brain Res. 1990, 55, 95–102. [CrossRef]
19. Prinz, M.; Priller, J. Microglia and brain macrophages in the molecular age: From origin to neuropsychiatric disease. Nat. Rev. Neurosci. 2014, 15, 300–312. [CrossRef] [PubMed]
20. Bennett, M.L.; Bennett, F.C.; Liddelow, S.A.; Ajami, B.; Zamanian, J.L.; Fernhoff, N.B.; Mulinyawe, S.B.; Bohlen, C.J.; Adil, A.; Tucker, A.; et al. New tools for studying microglia in the mouse and human CNS. Proc. Natl. Acad. Sci. USA 2016, 113, E1738–E1746. [CrossRef] [PubMed]
21. Sousa, C.; Biber, K.; Michelucci, A. Cellular and Molecular Characterization of Microglia: A Unique Immune Cell Population. Front. Immunol. 2017, 8, 198. [CrossRef] [PubMed]
22. Korzhevskii, D.E.; Kirik, O.V. Brain Microglia and Microglial Markers. Neurosci. Behav. Physiol. 2016, 46, 284–290. [CrossRef]
23. Badie, B.; Schartner, J.M. Flow Cytometric Characterization of Tumor-associated Macrophages in Experimental Gliomas. Neurosurgery 2000, 46, 957–962. [CrossRef] [PubMed]
24. Müller, A.; Brandenburg, S.; Turkowski, K.; Müller, S.; Vajkoczy, P. Resident microglia, and not peripheral macrophages, are the main source of brain tumor mononuclear cells. Int. J. Cancer 2014, 137, 278–288. [CrossRef] [PubMed]
25. Satoh, J.; Kino, Y.; Asahina, N.; Takitani, M.; Miyoshi, J.; Ishida, T.; Saito, Y. TMEM119 marks a subset of microglia in the human brain. Neuropathology 2016, 36, 39–49. [CrossRef] [PubMed]
26. McCarthy, K.D.; de Vellis, J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J. Cell Biol. 1980, 85, 890–902. [CrossRef] [PubMed]
27. Giulian, D.; Baker, T.J. Characterization of ameboid microglia isolated from developing mammalian brain. J. Neurosci. 1986, 6, 2163–2178. [PubMed]
28. Kees, T.; Lohr, J.; Noack, J.; Mora, R.; Gdynia, G.; Tödt, G.; Ernst, A.; Radlwimmer, B.; Falk, C.S.; Herold-Mende, C.; et al. Microglia isolated from patients with glioma gain antitumor activities on poly (I:C) stimulation. Neuro-Oncology 2011, 14, 64–78. [CrossRef] [PubMed]
29. Blasi, E.; Barluzzi, R.; Bocchini, V.; Mazzolla, R.; Bistoni, F. Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus. J. Neuroimmunol. 1990, 27, 229–237. [CrossRef]
30. Janabi, N.; Peudenier, S.; Héron, B.; Ng, K.H.; Tardieu, M. Establishment of human microglial cell lines after transfection of primary cultures of embryonic microglial cells with the SV40 large T antigen. Neurosci. Lett. 1995, 195, 105–108. [CrossRef]
31. Nagai, A.; Nakagawa, E.; Hatori, K.; Choi, H.B.; McLarnon, J.G.; Lee, M.A.; Kim, S.U. Generation and characterization of immortalized human microglial cell lines: Expression of cytokines and chemokines. Neurobiol. Dis. 2001, 8, 1057–1068. [CrossRef] [PubMed]
32. Henn, A.; Lund, S.; Hedtjärn, M.; Schrattenholz, A.; Pörzgen, P.; Leist, M. The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation. ALTEX 2009, 26, 83–94. [CrossRef] [PubMed]
33. Das, A.; Kim, S.H.; Arifuzzaman, S.; Yoon, T.; Chai, J.C.; Lee, Y.S.; Park, K.S.; Jung, K.H.; Chai, Y.G. Transcriptome sequencing reveals that LPS-triggered transcriptional responses in established microglia BV2 cell lines are poorly representative of primary microglia. J. Neuroinflamm. 2016, 13, 182. [CrossRef] [PubMed]
34. Horvath, R.J.; Nutile-McMenemy, N.; Alkaitis, M.S.; Deleo, J.A. Differential migration, LPS-induced cytokine, chemokine, and NO expression in immortalized BV-2 and HAPI cell lines and primary microglial cultures. J. Neurochem. 2008, 107, 557–569. [CrossRef] [PubMed]
35. Marek, R.; Caruso, M.; Rostami, A.; Grinspan, J.B.; Das Sarma, J. Magnetic cell sorting: A fast and effective method of concurrent isolation of high purity viable astrocytes and microglia from neonatal mouse brain tissue. J. Neurosci. Methods 2008, 175, 108–118. [CrossRef] [PubMed]
36. Losciuto, S.; Dorban, G.; Gabel, S.; Gustin, A.; Hoenen, C.; Grandbarbe, L.; Heuschling, P.; Heurtaux, T. An efficient method to limit microglia-dependent effects in astroglial cultures. J. Neurosci. Methods 2012, 207, 59–71. [CrossRef] [PubMed]
37. Tsuchiya, T.; Park, K.C.; Toyonaga, S.; Yamada, S.M.; Nakabayashi, H.; Nakai, E.; Ikawa, N.; Furuya, M.; Tominaga, A.; Shimizu, K. Characterization of microglia induced from mouse embryonic stem cells and their migration into the brain parenchyma. J. Neuroimmunol. 2005, 160, 210–218. [CrossRef] [PubMed]
38. Lin, Y.; Chen, G. Embryoid body formation from human pluripotent stem cells in chemically defined E8 media. In StemBook; Harvard Stem Cell Institute: Cambridge, MA, USA, 2008.
39. Jung, S.; Aliberti, J.; Graemmel, P.; Sunshine, M.J.; Kreutzberg, G.W.; Sher, A.; Littman, D.R. Analysis of Fractalkine Receptor CX3CR1 Function by Targeted Deletion and Green Fluorescent Protein Reporter Gene Insertion. Mol. Cell. Biol. 2000, 20, 4106–4114. [CrossRef] [PubMed]
40. London, A.; Benhar, I.; Mattapallil, M.J.; Mack, M.; Caspi, R.R.; Schwartz, M. Functional macrophage heterogeneity in a mouse model of autoimmune central nervous system pathology. J. Immunol. Baltim. 2013, 190, 3570–3578. [CrossRef] [PubMed]
41. Ransohoff, R.M.; Perry, V.H. Microglial physiology: Unique stimuli, specialized responses. Annu. Rev. Immunol. 2009, 27, 119–145. [CrossRef] [PubMed]
42. Humpel, C. Organotypic brain slice cultures: A review. Neuroscience 2015, 305, 86–98. [CrossRef] [PubMed]
43. Van Rooijen, N.; Hendrikx, E. Liposomes for specific depletion of macrophages from organs and tissues. Methods Mol. Biol. 2010, 605, 189–203. [CrossRef] [PubMed]
44. Nimmerjahn, A.; Kirchhoff, F.; Helmchen, F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308, 1314–1318. [CrossRef] [PubMed]
45. Bayerl, S.H.; Niesner, R.; Cseresnyes, Z.; Radbruch, H.; Pohlan, J.; Brandenburg, S.; Czabanka, M.A.; Vajkoczy, P. Time lapse in vivo microscopy reveals distinct dynamics of microglia-tumor environment interactions—A new role for the tumor perivascular space as highway for trafficking microglia. Glia 2016, 64, 1210–1226. [CrossRef] [PubMed]
46. Dailey, M.E.; Waite, M. Confocal imaging of microglial cell dynamics in hippocampal slice cultures. Methods 1999, 18, 222–230. [CrossRef] [PubMed]
47. Kurpius, D.; Nolley, E.P.; Dailey, M.E. Purines induce directed migration and rapid homing of microglia to injured pyramidal neurons in developing hippocampus. Glia 2007, 55, 873–884. [CrossRef] [PubMed]
48. Boehm, U.; Klamp, T.; Groot, M.; Howard, J.C. Cellular responses to interferon-gamma. Annu. Rev. Immunol. 1997, 15, 749–795. [CrossRef] [PubMed]
49. Colton, C.A.; Wilcock, D.M. Assessing activation states in microglia. CNS Neurol. Disord. Drug Targets 2010, 9, 174–191. [CrossRef] [PubMed]
50. Varnum, M.M.; Ikezu, T. The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer’s disease brain. Arch. Immunol. Ther. Exp. (Warsz.) 2012, 60, 251–266. [CrossRef] [PubMed]
51. Boche, D.; Perry, V.H.; Nicoll, J.A. Review: Activation patterns of microglia and their identification in the human brain. Neuropathol. Appl. Neurobiol. 2013, 39, 3–18. [CrossRef] [PubMed]
52. Orihuela, R.; McPherson, C.A.; Harry, G.J. Microglial M1/M2 polarization and metabolic states. Br. J. Pharmacol. 2016, 173, 649–665. [CrossRef] [PubMed]
53. Mantovani, A.; Sozzani, S.; Locati, M.; Allavena, P.; Sica, A. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23, 549–555. [CrossRef]
54. Shaked, I.; Porat, Z.; Gersner, R.; Kipnis, J.; Schwartz, M. Early activation of microglia as antigen-presenting cells correlates with T cell-mediated protection and repair of the injured central nervous system. J. Neuroimmunol. 2004, 146, 84–93. [CrossRef] [PubMed]
55. MacMicking, J.; Xie, Q.W.; Nathan, C. Nitric oxide and macrophage function. Annu. Rev. Immunol. 1997, 15, 323–350. [CrossRef] [PubMed]
56. Villalta, S.A.; Nguyen, H.X.; Deng, B.; Gotoh, T.; Tidball, J.G. Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum. Mol. Genet. 2009, 18, 482–496. [CrossRef] [PubMed]
57. Davalos, D.; Grutzendler, J.; Yang, G.; Kim, J.V.; Zuo, Y.; Jung, S.; Littman, D.R.; Dustin, M.L.; Gan, W.-B. ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 2005, 8, 752–758. [CrossRef] [PubMed]
58. Town, T.; Nikolic, V.; Tan, J. The microglial “activation” continuum: From innate to adaptive responses. J. Neuroinflamm. 2005, 2, 24. [CrossRef] [PubMed]
59. Rőszer, T. Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms. Mediat. Inflamm. 2015, 2015, 816460. [CrossRef] [PubMed]
60. Nathan, C.F.; Murray, H.W.; Wiebe, M.E.; Rubin, B.Y. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J. Exp. Med. 1983, 158, 670–689. [CrossRef] [PubMed]
61. Henkel, J.S.; Beers, D.R.; Zhao, W.; Appel, S.H. Microglia in ALS: The good, the bad, and the resting. J. Neuroimmune Pharmacol. 2009, 4, 389–398. [CrossRef] [PubMed]
62. Colton, C.A. Heterogeneity of microglial activation in the innate immune response in the brain. J. Neuroimmune Pharmacol. 2009, 4, 399–418. [CrossRef] [PubMed]
63. Roberts, E.S.; Masliah, E.; Fox, H.S. CD163 identifies a unique population of ramified microglia in HIV encephalitis (HIVE). J. Neuropathol. Exp. Neurol. 2004, 63, 1255–1264. [CrossRef] [PubMed]
64. Mantovani, A.; Sica, A.; Sozzani, S.; Allavena, P.; VECCHI, A.; Locati, M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25, 677–686. [CrossRef] [PubMed]
65. Stein, M.; Keshav, S.; Harris, N.; Gordon, S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: A marker of alternative immunologic macrophage activation. J. Exp. Med. 1992, 176, 287–292. [CrossRef] [PubMed]
66. Loke, P.; Nair, M.G.; Parkinson, J.; Guiliano, D.; Blaxter, M.; Allen, J.E. IL-4 dependent alternatively-activated macrophages have a distinctive in vivo gene expression phenotype. BMC Immunol. 2002, 3, 7. [CrossRef]
67. Watanabe, K.; Jose, P.J.; Rankin, S.M. Eotaxin-2 generation is differentially regulated by lipopolysaccharide and IL-4 in monocytes and macrophages. J. Immunol. 2002, 168, 1911–1918. [CrossRef] [PubMed]
68. Sawada, M.; Suzumura, A.; Hosoya, H.; Marunouchi, T.; Nagatsu, T. Interleukin-10 inhibits both production of cytokines and expression of cytokine receptors in microglia. J. Neurochem. 1999, 72, 1466–1471. [CrossRef] [PubMed]
69. Tang, Y.; Le, W. Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases. Mol. Neurobiol. 2016, 53, 1181–1194. [CrossRef] [PubMed]
70. Nair, A.; Bonneau, R.H. Stress-induced elevation of glucocorticoids increases microglia proliferation through NMDA receptor activation. J. Neuroimmunol. 2006, 171, 72–85. [CrossRef] [PubMed]
71. Ummenthum, K.; Peferoen, L.A.N.; Finardi, A.; Baker, D.; Pryce, G.; Mantovani, A.; Bsibsi, M.; Bottazzi, B.; Peferoen-Baert, R.; van der Valk, P.; et al. Pentraxin-3 is upregulated in the central nervous system during MS and EAE, but does not modulate experimental neurological disease. Eur. J. Immunol. 2016, 46, 701–711. [CrossRef] [PubMed]
72. Hu, F.; a Dzaye, O.D.; Hahn, A.; Yu, Y.; Scavetta, R.J.; Dittmar, G.; Kaczmarek, A.K.; Dunning, K.R.; Ricciardelli, C.; Rinnenthal, J.L.; et al. Glioma-derived versican promotes tumor expansion via glioma-associated microglial/macrophages Toll-like receptor 2 signaling. Neuro-Oncology 2014, 17, 200–210. [CrossRef] [PubMed]
73. Komohara, Y.; Ohnishi, K.; Kuratsu, J.; Takeya, M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J. Pathol. 2008, 216, 15–24. [CrossRef] [PubMed]
74. Shemer, A.; Erny, D.; Jung, S.; Prinz, M. Microglia Plasticity during Health and Disease: An Immunological Perspective. Trends Immunol. 2015, 36, 614–624. [CrossRef] [PubMed]
75. Martinez, F.O.; Gordon, S. The M1 and M2 paradigm of macrophage activation: Time for reassessment. F1000Prime Rep. 2014, 6, 13. [CrossRef] [PubMed]
76. Rosario, A.M.; Cruz, P.E.; Ceballos-Diaz, C.; Strickland, M.R.; Siemienski, Z.; Pardo, M.; Schob, K.-L.; Li, A.; Aslanidi, G.V.; Srivastava, A.; et al. Microglia-specific targeting by novel capsid-modified AAV6 vectors. Mol. Ther. Methods Clin. Dev. 2016, 3, 16026. [CrossRef] [PubMed]
77. Imai, Y.; Ibata, I.; Ito, D.; Ohsawa, K.; Kohsaka, S. A novel gene iba1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage. Biochem. Biophys. Res. Commun. 1996, 224, 855–862. [CrossRef] [PubMed]
78. Gautier, E.L.; Shay, T.; Miller, J.; Greter, M.; Jakubzick, C.; Ivanov, S.; Helft, J.; Chow, A.; Elpek, K.G.; Gordonov, S.; et al. Immunological Genome Consortium Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat. Immunol. 2012, 13, 1118–1128. [CrossRef] [PubMed]
79. Prinz, M.; Priller, J.; Sisodia, S.S.; Ransohoff, R.M. Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat. Neurosci. 2011, 14, 1227–1235. [CrossRef] [PubMed]
80. Gordon, S.; Hamann, J.; Lin, H.-H.; Stacey, M. F4/80 and the related adhesion-GPCRs. Eur. J. Immunol. 2011, 41, 2472–2476. [CrossRef] [PubMed]
81. Mizutani, M.; Pino, P.A.; Saederup, N.; Charo, I.F.; Ransohoff, R.M.; Cardona, A.E. The Fractalkine Receptor but Not CCR2 Is Present on Microglia from Embryonic Development throughout Adulthood. J. Immunol. 2011, 188, 29–36. [CrossRef] [PubMed]
82. Feng, X.; Szulzewsky, F.; Yerevanian, A.; Chen, Z.; Heinzmann, D.; Rasmussen, R.D.; Alvarez-Garcia, V.; Kim, Y.; Wang, B.; Tamagno, I.; et al. Loss of CX3CR1 increases accumulation of inflammatory monocytes and promotes gliomagenesis. Oncotarget 2015, 6, 15077–15094. [CrossRef] [PubMed]
83. Edwards, J.P.; Zhang, X.; Frauwirth, K.A.; Mosser, D.M. Biochemical and functional characterization of three activated macrophage populations. J. Leukoc. Biol. 2006, 80, 1298–1307. [CrossRef] [PubMed]
84. Kennedy, B.C.; Showers, C.R.; Anderson, D.E.; Anderson, L.; Canoll, P.; Bruce, J.N.; Anderson, R.C.E. Tumor-Associated Macrophages in Glioma: Friend or Foe? J. Oncol. 2013, 2013, 486912. [CrossRef] [PubMed]
85. Verdijk, P.; van Veelen, P.A.; de Ru, A.H.; Hensbergen, P.J.; Mizuno, K.; Koerten, H.K.; Koning, F.; Tensen, C.P.; Mommaas, A.M. Morphological changes during dendritic cell maturation correlate with cofilin activation and translocation to the cell membrane. Eur. J. Immunol. 2004, 34, 156–164. [CrossRef] [PubMed]
86. Zeiner, P.S.; Preusse, C.; Blank, A.-E.; Zachskorn, C.; Baumgarten, P.; Caspary, L.; Braczynski, A.K.; Weissenberger, J.; Bratzke, H.; Reiß, S.; et al. MIF Receptor CD74 is Restricted to Microglia/Macrophages, Associated with a M1-Polarized Immune Milieu and Prolonged Patient Survival in Gliomas. Brain Pathol. 2014, 25, 491–504. [CrossRef] [PubMed]
87. Abou-Ghazal, M.; Yang, D.S.; Qiao, W.; Reina-Ortiz, C.; Wei, J.; Kong, L.-Y.; Fuller, G.N.; Hiraoka, N.; Priebe, W.; Sawaya, R.; et al. The Incidence, Correlation with Tumor Infiltrating Inflammation, and Prognosis of p-STAT3 Expression in Human Gliomas. Clin. Cancer Res. 2008, 14, 8228–8235. [CrossRef] [PubMed]
88. Zhang, J.; Sarkar, S.; Cua, R.; Zhou, Y.; Hader, W.; Yong, V.W. A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2/CCR2/interleukin-6 axis. Carcinogenesis 2012, 33, 312–319. [CrossRef] [PubMed]
89. Galea, I.; Palin, K.; Newman, T.A.; Van Rooijen, N.; Perry, V.H.; Boche, D. Mannose receptor expression specifically reveals perivascular macrophages in normal, injured, and diseased mouse brain. Glia 2005, 49, 375–384. [CrossRef] [PubMed]
90. Raes, G.; De Baetselier, P.; Noël, W.; Beschin, A.; Brombacher, F.; Hassanzadeh Gh, G. Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages. J. Leukoc. Biol. 2002, 71, 597–602. [PubMed]
91. Desbaillets, I.; Tada, M.; De Tribolet, N.; Diserens, A.-C.; Hamou, M.-F.; Van Meir, E.G. Human astrocytomas and glioblastomas express monocyte chemoattractant protein-1 (MCP-1) in vivo and in vitro. Int. J. Cancer 1994, 58, 240–247. [CrossRef] [PubMed]
92. Platten, M.; Kretz, A.; Naumann, U.; Aulwurm, S.; Egashira, K.; Isenmann, S.; Weller, M. Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. Ann. Neurol. 2003, 54, 388–392. [CrossRef] [PubMed]
93. Kuratsu, J.; Yoshizato, K.; Yoshimura, T.; Leonard, E.J.; Takeshima, H.; Ushio, Y. Quantitative study of monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma. J. Natl. Cancer Inst. 1993, 85, 1836–1839. [CrossRef] [PubMed]
94. Sun, W.; Li, W.-J.; Wei, F.-Q.; Wong, T.-S.; Lei, W.-B.; Zhu, X.-L.; Li, J.; Wen, W.-P. Blockade of MCP-1/CCR4 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinoma. Oncotarget 2016, 7, 37714–37727. [CrossRef] [PubMed]
95. Okada, M. Tumor-associated macrophage/microglia infiltration in human gliomas is correlated with MCP-3, but not MCP-1. Int. J. Oncol. 2009, 34, 1621–1627. [PubMed]
96. Wang, S.-C.; Hong, J.-H.; Hsueh, C.; Chiang, C.-S. Tumor-secreted SDF-1 promotes glioma invasiveness and TAM tropism toward hypoxia in a murine astrocytoma model. Lab. Investig. 2011, 92, 151–162. [CrossRef] [PubMed]
97. Pyonteck, S.M.; Akkari, L.; Schuhmacher, A.J.; Bowman, R.L.; Sevenich, L.; Quail, D.F.; Olson, O.C.; Quick, M.L.; Huse, J.T.; Teijeiro, V.; et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 2013, 19, 1264–1272. [CrossRef] [PubMed]
98. Sielska, M.; Przanowski, P.; Wylot, B.; Gabrusiewicz, K.; Maleszewska, M.; Kijewska, M.; Zawadzka, M.; Kucharska, J.; Vinnakota, K.; Kettenmann, H.; et al. Distinct roles of CSF family cytokines in macrophage infiltration and activation in glioma progression and injury response. J. Pathol. 2013, 230, 310–321. [CrossRef] [PubMed]
99. Nolte, C.; Kirchhoff, F.; Kettenmann, H. Epidermal growth factor is a motility factor for microglial cells in vitro: Evidence for EGF receptor expression. Eur. J. Neurosci. 1997, 9, 1690–1698. [CrossRef] [PubMed]
100. Qu, W.; Tian, D.; Guo, Z.; Fang, J.; Zhang, Q.; Yu, Z.; Xie, M.; Zhang, H.; Lü, J.; Wang, W. Inhibition of EGFR/MAPK signaling reduces microglial inflammatory response and the associated secondary damage in rats after spinal cord injury. J. Neuroinflamm. 2012, 9, 178. [CrossRef] [PubMed]
101. Qu, W.-S.; Liu, J.-L.; Li, C.-Y.; Li, X.; Xie, M.-J.; Wang, W.; Tian, D.-S. Rapidly activated epidermal growth factor receptor mediates lipopolysaccharide-triggered migration of microglia. Neurochem. Int. 2015, 90, 85–92. [CrossRef] [PubMed]
102. Bettinger, I.; Thanos, S.; Paulus, W. Microglia promote glioma migration. Acta Neuropathol. 2002, 103, 351–355. [CrossRef] [PubMed]
103. Bodmer, S.; Strommer, K.; Frei, K.; Siepl, C.; de Tribolet, N.; Heid, I.; Fontana, A. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J. Immunol. 1989, 143, 3222–3229. [PubMed]
104. Samuels, V.; Barrett, J.M.; Bockman, S.; Pantazis, C.G.; Allen, M.B. Immunocytochemical study of transforming growth factor expression in benign and malignant gliomas. Am. J. Pathol. 1989, 134, 894–902. [PubMed]
105. Kaminska, B.; Kocyk, M.; Kijewska, M. TGF beta signaling and its role in glioma pathogenesis. Adv. Exp. Med. Biol. 2013, 986, 171–187. [CrossRef] [PubMed]
106. Wick, W.; Platten, M.; Weller, M. Glioma cell invasion: Regulation of metalloproteinase activity by TGF-beta. J. Neurooncol. 2001, 53, 177–185. [CrossRef] [PubMed]
107. Ramachandran, R.K.; Sørensen, M.D.; Aaberg-Jessen, C.; Hermansen, S.K.; Kristensen, B.W. Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas. PLoS ONE 2017, 12, e0172234. [CrossRef] [PubMed]
108. Markovic, D.S.; Vinnakota, K.; Chirasani, S.; Synowitz, M.; Raguet, H.; Stock, K.; Sliwa, M.; Lehmann, S.; Kalin, R.; van Rooijen, N.; et al. Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proc. Natl. Acad. Sci. USA 2009, 106, 12530–12535. [CrossRef] [PubMed]
109. Vinnakota, K.; Hu, F.; Ku, M.C.; Georgieva, P.B.; Szulzewsky, F.; Pohlmann, A.; Waiczies, S.; Waiczies, H.; Niendorf, T.; Lehnardt, S.; et al. Toll-like receptor 2 mediates microglia/brain macrophage MT1-MMP expression and glioma expansion. Neuro-Oncology 2013, 15, 1457–1468. [CrossRef] [PubMed]
110. Da Fonseca, A.C.C.; Wang, H.; Fan, H.; Chen, X.; Zhang, I.; Zhang, L.; Lima, F.R.S.; Badie, B. Increased expression of stress inducible protein 1 in glioma-associated microglia/macrophages. J. Neuroimmunol. 2014, 274, 71–77. [CrossRef] [PubMed]
111. De, I.; Steffen, M.D.; Clark, P.A.; Patros, C.J.; Sokn, E.; Bishop, S.M.; Litscher, S.; Maklakova, V.I.; Kuo, J.S.; Rodriguez, F.J.; et al. CSF1 Overexpression Promotes High-Grade Glioma Formation without Impacting the Polarization Status of Glioma-Associated Microglia and Macrophages. Cancer Res. 2016, 76, 2552–2560. [CrossRef] [PubMed]
112. Coniglio, S.J.; Eugenin, E.; Dobrenis, K.; Stanley, E.R.; West, B.L.; Symons, M.H.; Segall, J.E. Microglial Stimulation of Glioblastoma Invasion Involves Epidermal Growth Factor Receptor (EGFR) and Colony Stimulating Factor 1 Receptor (CSF-1R) Signaling. Mol. Med. 2012, 18, 519–527. [CrossRef] [PubMed]
113. Brennan, C.W.; Verhaak, R.G.W.; McKenna, A.; Campos, B.; Noushmehr, H.; Salama, S.R.; Zheng, S.; Chakravarty, D.; Sanborn, J.Z.; Berman, S.H.; et al. TCGA Research Network The somatic genomic landscape of glioblastoma. Cell 2013, 155, 462–477. [CrossRef] [PubMed]
114. Huang, P.H.; Xu, A.M.; White, F.M. Oncogenic EGFR signaling networks in glioma. Sci. Signal. 2009, 2, re6. [CrossRef] [PubMed]
115. Brandenburg, S.; Müller, A.; Turkowski, K.; Radev, Y.T.; Rot, S.; Schmidt, C.; Bungert, A.D.; Acker, G.; Schorr, A.; Hippe, A.; et al. Resident microglia rather than peripheral macrophages promote vascularization in brain tumors and are source of alternative pro-angiogenic factors. Acta Neuropathol. 2016, 131, 365–378. [CrossRef] [PubMed]
116. Piao, Y.; Liang, J.; Holmes, L.; Zurita, A.J.; Henry, V.; Heymach, J.V.; de Groot, J.F. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro-Oncology 2012, 14, 1379–1392. [CrossRef] [PubMed]
117. Piperi, C.; Samaras, V.; Levidou, G.; Kavantzas, N.; Boviatsis, E.; Petraki, K.; Grivas, A.; Barbatis, C.; Varsos, V.; Patsouris, E.; et al. Prognostic significance of IL-8-STAT-3 pathway in astrocytomas: Correlation with IL-6, VEGF and microvessel morphometry. Cytokine 2011, 55, 387–395. [CrossRef] [PubMed]
118. Kierdorf, K.; Fritz, G. RAGE regulation and signaling in inflammation and beyond. J. Leukoc. Biol. 2013, 94, 55–68. [CrossRef] [PubMed]
119. Chen, X.; Zhang, L.; Zhang, I.Y.; Liang, J.; Wang, H.; Ouyang, M.; Wu, S.; da Fonseca, A.C.C.; Weng, L.; Yamamoto, Y.; et al. RAGE Expression in Tumor-Associated Macrophages Promotes Angiogenesis in Glioma. Cancer Res. 2014, 74, 7285–7297. [CrossRef] [PubMed]
120. Paulus, W.; Baur, I.; Huettner, C.; Schmausser, B.; Roggendorf, W.; Schlingensiepen, K.H.; Brysch, W. Effects of transforming growth factor-beta 1 on collagen synthesis, integrin expression, adhesion and invasion of glioma cells. J. Neuropathol. Exp. Neurol. 1995, 54, 236–244. [CrossRef] [PubMed]
121. Wagner, S.; Czub, S.; Greif, M.; Vince, G.H.; Süss, N.; Kerkau, S.; Rieckmann, P.; Roggendorf, W.; Roosen, K.; Tonn, J.C. Microglial/macrophage expression of interleukin 10 in human glioblastomas. Int. J. Cancer 1999, 82, 12–16. [CrossRef]
122. Kiefer, R.; Supler, M.L.; Toyka, K.V.; Streit, W.J. In situ detection of transforming growth factor-beta mRNA in experimental rat glioma and reactive glial cells. Neurosci. Lett. 1994, 166, 161–164. [CrossRef]
123. Wesolowska, A.; Kwiatkowska, A.; Slomnicki, L.; Dembinski, M.; Master, A.; Sliwa, M.; Franciszkiewicz, K.; Chouaib, S.; Kaminska, B. Microglia-derived TGF-beta as an important regulator of glioblastoma invasion—An inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor. Oncogene 2008, 27, 918–930. [CrossRef] [PubMed]
124. Suzumura, A.; Sawada, M.; Yamamoto, H.; Marunouchi, T. Transforming growth factor-beta suppresses activation and proliferation of microglia in vitro. J. Immunol. 1993, 151, 2150–2158. [PubMed]
125. Hussain, S.F.; Yang, D.; Suki, D.; Aldape, K.; Grimm, E.; Heimberger, A.B. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro-Oncology 2006, 8, 261–279. [CrossRef] [PubMed]
126. Kostianovsky, A.M.; Maier, L.M.; Anderson, R.C.; Bruce, J.N.; Anderson, D.E. Astrocytic Regulation of Human Monocytic/Microglial Activation. J. Immunol. 2008, 181, 5425–5432. [CrossRef] [PubMed]
127. Badie, B.; Bartley, B.; Schartner, J. Differential expression of MHC class II and B7 costimulatory molecules by microglia in rodent gliomas. J. Neuroimmunol. 2002, 133, 39–45. [CrossRef]
128. Frei, K.; Lins, H.; Schwerdel, C.; Fontana, A. Antigen presentation in the central nervous system. The inhibitory effect of IL-10 on MHC class II expression and production of cytokines depends on the inducing signals and the type of cell analyzed. J. Immunol. 1994, 152, 2720–2728. [PubMed]
129. Zhang, L.; Alizadeh, D.; Van Handel, M.; Kortylewski, M.; Yu, H.; Badie, B. Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice. Glia 2009, 57, 1458–1467. [CrossRef] [PubMed]
130. Sato, T.; Terai, M.; Tamura, Y.; Alexeev, V.; Mastrangelo, M.J.; Selvan, S.R. Interleukin 10 in the tumor microenvironment: A target for anticancer immunotherapy. Immunol. Res. 2011, 51, 170–182. [CrossRef] [PubMed]
131. Huettner, C.; Czub, S.; Kerkau, S.; Roggendorf, W.; Tonn, J.C. Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Res. 1997, 17, 3217–3224. [PubMed]
132. Luwor, R.B.; Stylli, S.S.; Kaye, A.H. The role of Stat3 in glioblastoma multiforme. J. Clin. Neurosci. 2013, 20, 907–911. [CrossRef] [PubMed]
133. Mizoguchi, M.; Betensky, R.A.; Batchelor, T.T.; Bernay, D.C.; Louis, D.N.; Nutt, C.L. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: Correlation with EGFR status, tumor grade, and survival. J. Neuropathol. Exp. Neurol. 2006, 65, 1181–1188. [CrossRef] [PubMed]
134. Wang, H.; Wang, H.; Zhang, W.; Huang, H.J.; Liao, W.S.L.; Fuller, G.N. Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab. Investig. 2004, 84, 941–951. [CrossRef] [PubMed]
135. Lo, H.-W.; Cao, X.; Zhu, H.; Ali-Osman, F. Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin. Cancer Res. 2008, 14, 6042–6054. [CrossRef] [PubMed]
136. See, A.P.; Han, J.E.; Phallen, J.; Binder, Z.; Gallia, G.; Pan, F.; Jinasena, D.; Jackson, C.; Belcaid, Z.; Jeong, S.J.; et al. The role of STAT3 activation in modulating the immune microenvironment of GBM. J. Neurooncol. 2012, 110, 359–368. [CrossRef] [PubMed]
137. Iwamaru, A.; Szymanski, S.; Iwado, E.; Aoki, H.; Yokoyama, T.; Fokt, I.; Hess, K.; Conrad, C.; Madden, T.; Sawaya, R.; et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 2007, 26, 2435–2444. [CrossRef] [PubMed]
138. Da Fonseca, A.C.C.; Badie, B. Microglia and macrophages in malignant gliomas: Recent discoveries and implications for promising therapies. Clin. Dev. Immunol. 2013, 2013, 264124. [CrossRef] [PubMed]
139. Badie, B.; Schartner, J.; Prabakaran, S.; Paul, J.; Vorpahl, J. Expression of Fas ligand by microglia: Possible role in glioma immune evasion. J. Neuroimmunol. 2001, 120, 19–24. [CrossRef]
140. Didenko, V.V.; Ngo, H.N.; Minchew, C.; Baskin, D.S. Apoptosis of T lymphocytes invading glioblastomas multiforme: A possible tumor defense mechanism. J. Neurosurg. 2002, 96, 580–584. [CrossRef] [PubMed]
141. Ford, A.L.; Foulcher, E.; Lemckert, F.A.; Sedgwick, J.D. Microglia induce CD4 T lymphocyte final effector function and death. J. Exp. Med. 1996, 184, 1737–1745. [CrossRef] [PubMed]
142. Ebner, F.; Brandt, C.; Thiele, P.; Richter, D.; Schliesser, U.; Siffrin, V.; Schueler, J.; Stubbe, T.; Ellinghaus, A.; Meisel, C.; et al. Microglial activation milieu controls regulatory T cell responses. J. Immunol. 2013, 191, 5594–5602. [CrossRef] [PubMed]
143. Han, J.; Harris, R.A.; Zhang, X.-M. An updated assessment of microglia depletion: Current concepts and future directions. Mol. Brain 2017, 10, 25. [CrossRef] [PubMed]
144. Mercurio, L.; Ajmone-Cat, M.A.; Cecchetti, S.; Ricci, A.; Bozzuto, G.; Molinari, A.; Manni, I.; Pollo, B.; Scala, S.; Carpinelli, G.; et al. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model. J. Exp. Clin. Cancer Res. 2016, 35, 55. [CrossRef] [PubMed]
145. Ieranò, C.; Portella, L.; Lusa, S.; Salzano, G.; D’Alterio, C.; Napolitano, M.; Buoncervello, M.; Macchia, D.; Spada, M.; Barbieri, A.; et al. CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis. Nanoscale 2016, 8, 7562–7571. [CrossRef] [PubMed]
146. Fonseca, A.C.; Romão, L.; Amaral, R.F.; Assad Kahn, S.; Lobo, D.; Martins, S.; de Souza, J.M.; Moura-Neto, V.; Lima, F.R.S. Microglial stress inducible protein 1 promotes proliferation and migration in human glioblastoma cells. Neuroscience 2012, 200, 130–141. [CrossRef] [PubMed]
147. Cannarile, M.A.; Weisser, M.; Jacob, W.; Jegg, A.-M.; Ries, C.H.; Rüttinger, D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J. Immunother. Cancer 2017, 5, 53. [CrossRef] [PubMed]
148. Butowski, N.; Colman, H.; De Groot, J.F.; Omuro, A.M.; Nayak, L.; Wen, P.Y.; Cloughesy, T.F.; Marimuthu, A.; Haidar, S.; Perry, A.; et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: An Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-Oncology 2016, 18, 557–564. [CrossRef] [PubMed]
149. Quail, D.F.; Bowman, R.L.; Akkari, L.; Quick, M.L.; Schuhmacher, A.J.; Huse, J.T.; Holland, E.C.; Sutton, J.C.; Joyce, J.A. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science 2016, 352, aad3018. [CrossRef] [PubMed]
150. Pradel, L.P.; Ooi, C.-H.; Romagnoli, S.; Cannarile, M.A.; Sade, H.; Rüttinger, D.; Ries, C.H. Macrophage Susceptibility to Emactuzumab (RG7155) Treatment. Mol. Cancer Ther. 2016, 15, 3077–3086. [CrossRef] [PubMed]
151. Ries, C.H.; Cannarile, M.A.; Hoves, S.; Benz, J.; Wartha, K.; Runza, V.; Rey-Giraud, F.; Pradel, L.P.; Feuerhake, F.; Klaman, I.; et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 2014, 25, 846–859. [CrossRef] [PubMed]
152. Peng, S.-B.; Zhang, X.; Paul, D.; Kays, L.M.; Gough, W.; Stewart, J.; Uhlik, M.T.; Chen, Q.; Hui, Y.-H.; Zamek-Gliszczynski, M.J.; et al. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models. Mol. Cancer Ther. 2015, 14, 480–490. [CrossRef] [PubMed]
153. Li, X.; Guo, H.; Yang, Y.; Meng, J.; Liu, J.; Wang, C.; Xu, H. A designed peptide targeting CXCR4 displays anti-acute myelocytic leukemia activity in vitro and in vivo. Sci. Rep. 2014, 4, 6610. [CrossRef] [PubMed]
154. Guo, H.; Ge, Y.; Li, X.; Yang, Y.; Meng, J.; Liu, J.; Wang, C.; Xu, H. Targeting the CXCR4/CXCL12 axis with the peptide antagonist E5 to inhibit breast tumor progression. Signal Transduct. Target. Ther. 2017, 2, 17033. [CrossRef] [PubMed]
155. Burger, M.; Glodek, A.; Hartmann, T.; Schmitt-Gräff, A.; Silberstein, L.E.; Fujii, N.; Kipps, T.J.; Burger, J.A. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene 2003, 22, 8093–8101. [CrossRef] [PubMed]
156. Portella, L.; Vitale, R.; De Luca, S.; D’Alterio, C.; Ieranò, C.; Napolitano, M.; Riccio, A.; Polimeno, M.N.; Monfregola, L.; Barbieri, A.; et al. Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases. PLoS ONE 2013, 8, e74548. [CrossRef] [PubMed]
157. Kioi, M.; Vogel, H.; Schultz, G.; Hoffman, R.M.; Harsh, G.R.; Brown, J.M. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Investig. 2010, 120, 694–705. [CrossRef] [PubMed]
158. Wang, S.-C.; Yu, C.-F.; Hong, J.-H.; Tsai, C.-S.; Chiang, C.-S. Radiation Therapy-Induced Tumor Invasiveness Is Associated with SDF-1-Regulated Macrophage Mobilization and Vasculogenesis. PLoS ONE 2013, 8, e69182. [CrossRef] [PubMed]
159. Zabel, B.A.; Wang, Y.; Lewén, S.; Berahovich, R.D.; Penfold, M.E.T.; Zhang, P.; Powers, J.; Summers, B.C.; Miao, Z.; Zhao, B.; et al. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J. Immunol. 2009, 183, 3204–3211. [CrossRef] [PubMed]
160. Dillmann, F.; Veldwijk, M.R.; Laufs, S.; Sperandio, M.; Calandra, G.; Wenz, F.; Zeller, W.J.; Fruehauf, S. Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib. Leuk. Lymphoma 2009, 50, 1676–1686. [CrossRef] [PubMed]
161. Salacz, M.E.; Kast, R.E.; Saki, N.; Brüning, A.; Karpel-Massler, G.; Halatsch, M.-E. Toward a noncytotoxic glioblastoma therapy: Blocking MCP-1 with the MTZ Regimen. OncoTargets Ther. 2016, 9, 2535–2545. [CrossRef] [PubMed]
162. Horiguchi, A.; Asano, T.; Kuroda, K.; Sato, A.; Asakuma, J.; Ito, K.; Hayakawa, M.; Sumitomo, M.; Asano, T. STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br. J. Cancer 2010, 102, 1592–1599. [CrossRef] [PubMed]
163. Wu, A.; Wei, J.; Kong, L.-Y.; Wang, Y.; Priebe, W.; Qiao, W.; Sawaya, R.; Heimberger, A.B. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro-Oncology 2010, 12, 1113–1125. [CrossRef] [PubMed]
164. Elmore, M.R.P.; Najafi, A.R.; Koike, M.A.; Dagher, N.N.; Spangenberg, E.E.; Rice, R.A.; Kitazawa, M.; Matusow, B.; Nguyen, H.; West, B.L.; et al. Colony-Stimulating Factor 1 Receptor Signaling Is Necessary for Microglia Viability, Unmasking a Microglia Progenitor Cell in the Adult Brain. Neuron 2014, 82, 380–397. [CrossRef] [PubMed]
165. Strachan, D.C.; Ruffell, B.; Oei, Y.; Bissell, M.J.; Coussens, L.M.; Pryer, N.; Daniel, D. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8(+) T cells. Oncoimmunology 2013, 2, e26968. [CrossRef] [PubMed]
166. Rios, A.; Hsu, S.H.; Blanco, A.; Buryanek, J.; Day, A.L.; McGuire, M.F.; Brown, R.E. Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide. Oncoscience 2016, 3, 156–163. [CrossRef] [PubMed]